Q-omics provides the consensus-scored WDR5B profile across patient tissues and cancer cell-line models. WDR5B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, WDR5B is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, WDR5B RNA expression shows 20,299 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where WDR5B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WDR5B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WDR5B survival associations across molecular data types. WDR5B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WDR5B RNA expression–survival associations across cancer types. High WDR5B expression shows unfavorable associations in MESO, LIHC and LUSC, but favorable associations in ACC, HNSC and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for WDR5B RNA expression.
This table summarizes WDR5B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for WDR5B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WDR5B shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, BLCA, COAD and STAD. The HNSC box plot shows higher WDR5B RNA expression in tumor versus normal tissue (log2 FC = +0.793, t-test p < 0.001).
This table shows molecular features associated with WDR5B in patient tissues and cancer cell lines. In patient samples, WDR5B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, WDR5B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
